Thus, we conclude that DCs loaded with EpiTCer beads, carrying several in silico predicted neoantigens, are more efficient in enriching for and activating tumor-specific CD8+ T cells from the blood, compared to tumor-lysate-loaded DC. The gene discussed is CD8A; the disease is neoplasm.